Beyond Weight Loss: How GLP-1 Receptor Agonists Are Rewriting Survival Outcomes in Non-Metastatic Breast Cancer
By Oncology Insights Desk Executive Summary Weight gain, altered basal metabolism, and chronic metabolic shifts are among the most persistent and distressing side effects experienced by individuals undergoing treatment for early-stage breast cancer. While historically viewed primarily as quality-of-life concerns, modern oncology increasingly recognizes metabolic dysfunction and obesity as critical drivers of adverse long-term clinical outcomes—including heightened risks of cancer recurrence, type 2 diabetes, and cardiovascular mortality. Beyond Weight Loss: How GLP-1 Receptor Agonists Are Rewriting Survival Outcomes in Non-Metastatic Breast Cancer At the ASCO Annual Meeting, landmark real-world findings led by Dr. Jasmine Sukumar revealed a compelling shift in survivorship science: non-metastatic breast cancer patients prescribed GLP-1 receptor agonists demonstrated a 95.8% five-year overall survival rate , compared to 89.5% in matched non-users. Supported by Conquer Cancer, the AS...